-
Product Insights
New![]()
Cipla Tuljapur Solar PV Park
Cipla Tuljapur Solar PV Park is a solar PV project located in Maharashtra, India. The project is owned by Ampin Energy Transition Pvt Ltd and was developed by Amp Energy Green Pvt Ltd. The project came online in 2020. Empower your strategies with our Cipla Tuljapur Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
New![]()
Cipla Tuljapur Solar PV Park 2
Cipla Tuljapur Solar PV Park 2 is a solar PV project located in Maharashtra, India. The project is owned and developed by Ampin Energy Transition Pvt Ltd. The project came online in 2022. Empower your strategies with our Cipla Tuljapur Solar PV Park 2 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and...
-
Company Insights
New![]()
Innovation and Patenting activity of Cipla Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cipla Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KM-001 in Palmoplantar Keratoderma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.KM-001 in Palmoplantar KeratodermaDrug Details:KM-001 is under development for the treatment of itch associated with moderate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Abacavir Sulfate + Lamivudine + Lopinavir + Ritonavir) in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Abacavir Sulfate + Lamivudine + Lopinavir + Ritonavir) in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
![]()
CIPLA – Pithampur Pharmaceutical Manufacturing Facility – Madhya Pradesh
Equip yourself with the essential tools needed to make informed and profitable decisions with our CIPLA - Pithampur Pharmaceutical Manufacturing Facility - Madhya Pradesh report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Company Profile
![]()
Cipla Ltd – Company Profile
Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products in therapeutic areas such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices, and conducts R&D to develop new...
Add to Basket -
Product Insights
![]()
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
![]()
Net Present Value Model: Aloxi
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Aloxi Drug Details Palonosetron hydrochloride (Aloxi,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – (abacavir sulfate + lamivudine + lopinavir + ritonavir)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (abacavir sulfate + lamivudine + lopinavir + ritonavir) Drug Details A fixed dose combination...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.